Zacks.com on MSN12h
DXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 ApprovalDexCom receives a warning letter from the FDA citing several issues with its popular G6 & G7 sensor manufacturing. The ...
The general mood among these heavyweight investors is divided, with 12% leaning bullish and 50% bearish. Among these notable ...
The "Diabetes Monitoring, Treatment and Drug Delivery Market Size, Share & Trends Analysis | United States | 2025-2031 | MedSuite | Includes: Insulin & GLP-1, Continuous Glucose Monitoring and 7 more" ...
As per a clinical study, smartwatches can help drive meaningful exercise routines and lifestyle changes to help people ...
A study confirms Raman Spectroscopy’s potential for noninvasive glucose monitoring, improving calibration and accuracy.
Abbott, Dexcom, Insulet, Medtronic and others are developing next-gen sensors, pumps and algorithms for type 2 diabetes ...
A company spokesperson said Dexcom plans to resolve the agency's concerns but stated no design changes were made to its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback